Stopping androgen treatment in patients with HAE - characterization of reasons and protocols and development of advice for patients and physicians

Stopping androgen treatment in patients with HAE - characterization of reasons and protocols and development of advice for patients and physicians - SHAERPA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024439

Enrollment

500

Registered

2021-05-31

Start date

2022-06-21

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D84.1

Interventions

Group 1: The aim is to determine why, how and with what consequences androgen therapy is discontinued in patients with hereditary angioedema (HAE).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with hereditary angioedema (HAE), in whom therapy with androgens has been discontinued.

Exclusion criteria

Exclusion criteria: Patients with hereditary angioedema who have not taken androgens.

Design outcomes

Primary

Measure	Time frame
Determine the reasons and circumstances that led patients with hereditary angioedema (HAE) to discontinue prophylactic treatment with androgens.	—

Secondary

Measure	Time frame
1) Characterise the reasons why patients with HAE discontinue the use of androgens for long-term prophylaxis. 2) Identify what protocols are in place for HAE patients to discontinue the use of androgens. 3) Generate data that informs how androgen use can be discontinued for patients and clinicians.	—

Countries

Brazil, China, France, Germany, Hungary, India, Oman, Peru, Portugal, Russia, South Africa, South Korea, Thailand

Contacts

Public ContactCarolina Vera Ayala

Klinik für Dermatologie, Allergologie und Venerologie, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin

carolina.vera@charite.de+49 030450518037

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026